bin, protein C, and protein S. A search for homozygosity of factor V Leiden appears advisable. These defects represent absolute contraindications to the use of OCT. Relative contraindications may be represented by other minor coagulation disorders such as heterozygous factor V Leiden, fibrinolysis defects, and a G-to-A 20210 prothrombin abnormality. Other noncoagulation-related conditions such as hypertension, liver damage, and obesity may represent absolute or relative contraindications to the use of OCT.
Summary: Oral contraceptive therapy (OCT) is widely used in the world. It is usually safe and effective but side effects are occasionally seen. Venous thromboembolism is one of the most feared side effects. To avoid this complication adequate guidelines are needed. These have to take into account family history, personal history, and suitable laboratory investigations. The presence of an idiopathic venous thrombosis in the family or in the personal history is of paramount importance. However it is often difficult to ascertain whether a venous thrombosis is idiopathic or not. Even when there is doubt, a coagulation study should be carried out. An adequate coagulation study in this case should include at least an evaluation of antithrom-Oral contraceptive therapy (OCT) is the most widely used means of contraception in the world (1) (2) (3) (4) . Approximately 100 million women are, at any given moment, using OCT. The use of these medications are associated with several side effects, the most important of which is thrombotic phenomena. This is particularly true if women on OCT show a congenital condition predisposing to thrombosis (5) (6) (7) (8) . These thrombotic phenomena involve mainly the venous system but, given certain circumstances, may also involve the arterial aspect of the blood circulation. The coagulation changes responsible for this increased incidence of thrombosis are variable and perhaps still not completely clarified (Table 1) .
We attempt on the basis of a long clinical experience in the field and literature search, to formulate guidelines and practical suggestions for the practicing physician that appear to represent a sound approach to prevent venous thromboembolism in women starting or taking oral contraceptive therapy. It is not clear yet whether the present recommendations in prescribing these compounds may be useful for arterial thrombotic complications but it is likely to be so. Venous thrombosis due to oral contraceptive therapy is a major health problem. The overall incidence of this complication has decreased over the past two to three decades due mainly to a more careful selection of patients and to the use of low dosage preparations. Despite these changes, it can be expected that in unselected women OCT may increase the risk of venous thrombosis at least fourfold with respect to agematched non-users (4, (9) (10) (11) (12) . Given an overall incidence of venous thrombosis in the general population of 1/1,000 to about 1/2,000 (11) and taking the lower figure because of the young age of OCT users, the incidence in OC-treated women could reach 1/400 or 0.25%. In limited or special populations, increased prevalence may be seen (5, 8) . It is impossible to screen all women who intend to start OCT (4). The cost would be unbearable and would not eliminate the self-prescription on part of the women. This self-prescription can reach about 25% of persons. Usually the physician gathers a family or personal history and then prescribes the medication of choice. In a minority of cases, the physician may ask for a few coagulation and liver function tests. Among the coagulation tests, prothrombin time (TP), partial thromboplastin time (PTT), and antithrombin (AT) are commonly ordered. The screening should be patient-oriented, namely limited to women who show some real potential thrombotic risks (13) (14) (15) (16) . Once this is established, the screening should be complete ( Table 2) .
Heterozygous antithrombin (AT) deficiency seems to be the most dangerous condition for the development of OCT-associated venous thromboembolism. In a series, approximately 80% of patients developed venous thrombosis on OCT (5, 8) . Furthermore the thrombosis occurred immediately after the onset of OCT, within one to two cycles. Patients with this defect should ab-stain absolutely from taking OCT. Interestingly patients with a defective heparin-binding site (AT type II c) at the heterozygous level do not seem to present thrombosis during OCT (17) .
Protein C and protein S deficiencies, both at the homozygous and heterozygous level, are also associated with a high risk of venous thrombosis and these defects should be considered an absolute contraindication to OCT (5, 8) . The thrombotic phenomena in this case seem to occur after an average of four to five cycles. Therefore the occurrence of a deep venous thrombosis after a few cycles may be interpreted as an indication of an occult thrombophilic state, namely a defect in one of these three main prothrombotic conditions. This has occurred many times because certain women were given OC without a proper family and personal history and without adequate laboratory tests. The previously mentioned deficiencies together with other coagulation-unrelated conditions such as myeloproliferative disorders, antiphospholipid antibody syndrome, hypertension, diabetes mellitus, and severe obesity, should be considered an absolute contraindication to OC therapy ( Table 3 ).
The approach may be different if one takes into account the two polymorphisms, recently described, namely factor V Leiden and the G-to-A 20210 prothrombin abnormality (8, 13, 14, 16) . These conditions, present in about 3% to 5% of the general population, are minor prothrombotic defects. In the case of FV Leiden it seems safe to assume that homozygous patients should abstain from taking OCT (8) .
As far as heterozygous patients are concerned there may be some doubts in the sense that the incidence of venous thromboembolism is increased as compared with normal counterparts but the thrombotic phenomena seem to occur after several cycles, about 12 to 14. This is approximately the time that OCT usually requires to cause thrombotic events in normal women. Therefore in cases of extreme need (endometriosis, intrauterine device intolerance, avoidance of a pregnancy for a previous child with mongolism, etc.), one may envisage short periods (3-4 months at most) of OCT under strict medical supervision (14) .
The value of the G-to-A 20210 prothrombin polymorphism is not clear yet. It could represent only a relative contraindication. There are conflicting reports in the literature and recently even homozygous patients have remained asymptomatic after long courses of OCT (18, 19) .
As far as the other so-called congenital prothrombotic risks (hyperhomocystinemia, defects of the fibrinolytic system) are concerned, no final conclusion can be drawn because observations are scanty. Heterozygous plasminogen deficiency does not seem to be associated with an increase in OCT-related venous thrombosis. This is probably due to the fact that plasminogen increases during OCT. All the previously mentioned coagulation defects could be considered, together with other coagulation-unrelated conditions, such as smoking and moderate obesity, as relative contraindications to OCT ( Table 4 ).
The positive family history is not always to be considered as an absolute contraindication. Only idiopathic venous thromboembolism in the family needs due attention and has to be considered so. The problem is that it is often difficult to positively ascertain, particularly on the basis of a medical history, that a thrombosis in a family member was idiopathic. This is particularly true when one deals with relatives of patients who may have only partial or indirect information. Secondary thromboses are usually due to pregnancy, puerperium, major orthopedic surgery, general surgery, immobilization from any cause, intravenous catheters, intravenous feeding, intravenous antiblastic drugs, heart failure, splints or casts, cancer, old age, hyperviscosity syndromes, nephrotic syndrome, and so on. Once the risk factor is removed or has disappeared, it is conceivable that no thrombophilic state is present. Besides the previously mentioned conditions, it is not known yet whether minor decreases in blood flow or minor vessel wall traumas that may be asymptomatic or go undetected might be, under certain circumstances, thrombogenic. Personal positive history may be more important even if the venous thrombosis appears to be associated with a known acquired and fleeting risk factor. In fact a deep venous thrombosis at a young age is always an important event that should alert the caring physician. A patient who presented a deep venous thrombosis secondary to a well-defined risk factor should always be considered as suspicious. In fact, risk factors, for example pregnancy, surgery, and so on, are a cause of symptomatic deep venous thrombosis in a minority of subjects, perhaps 5% to 10%. Therefore the great majority of subjects exposed to the same risk remain thrombosis-free at least clinically. A person who has had a risk-associated venous thrombosis should be thoroughly investigated and even if she is not found to have a prothrombotic defect should abstain from taking OCT. There is in fact always the possibility that she might have a hereto unknown predisposition to thrombosis. The conditions required for a safe OCT are summarized in Table 5 .
An important problem concerns the type of oral contraceptive to be prescribed (9, 10, (20) (21) (22) . It is not our intention to enter the hot and not always well-balanced and objective discussion about the difference between second-generation (levonorgestrel) versus third-generation progestins (gestoden, desogestrel) (23) (24) (25) (26) (27) (28) (29) 31, 32) . There seem to be a justified trend in considering the third-generation progestins slightly more thrombogenic as compared to the others. The alleged increased incidence of venous thrombosis in women using OC containing third-generation progestins requires further studies, mainly prospective ones. In fact, a relative risk of 2 in retrospective studies as that apparently present in this case is a small one and usually disappears in prospective studies. However, even in doubt, we think it is preferable to use preparations containing second-generation progestins, at the same low level of ethynilestradiol (0.030 mg). The prescribing physician should evaluate the alleged and possible benefits of third-generation progestins on low density lipoprotein versus the increased risk of venous thrombosis and make the final decision with regard to prescribing these compounds to only a special group of women (diabetics for example) (10, 12, 20) . As a general rule, it seems advisable that one should not start OCT using the third-generation progestins. On the contrary we do not think there are sufficient data to advise asymptomatic women already taking preparations containing third-generation progestins to switch to other types of oral contraceptives. In this regard the procedure adopted by the British Council of Family Physicians seemed unjustified and inappropriate. There was no need for a pill scare as happened in recent years (9, 10) . Providing all these guidelines are followed, it is likely that no major difference between the two groups of progestins exists. One has to remember that retrospective epidemiologic studies may not be completely reliable. For example, two groups of epidemiologists using the same computerized database reported opposite conclusions with regard to the effect of third-generation progestins (24) . The use of these studies in guiding clinical practice may be misleading (33) . Finally, because the nature of clotting changes induced by the different oral contraceptives are not completely known, it is difficult to draw sure conclusions (34) .
Another important observation concerns the unreliability of considering as an absolute proof of safety the fact that a woman about to resume OCT had taken it previously without complications. There are several examples of women who took OCT at the age of 20 or so and then showed a deep vein thrombosis at a later age on resumption of the same or a different preparation. A final point concerns the advisability of periodic interruption of the OCT. A 2-or 3-month suspension every year is advisable because it appears that such a lapse is required for the clotting system to revert to a basal state. Strictly correlated with this is the absolute need to suspend OCT immediately whenever other potentially thrombotic conditions appear (Table 6) .
Cautious resumption of the medication should be established not before at least 2 months after the event. There are, of course, medicolegal re- sponsibilities involved in the prescription of OCT. Adhesion to the guidelines and suggestions presented here may represent a safeguard. Should these guidelines be strictly adhered to, probably even the alleged difference between thirdand second-generation progestins may be overlooked and/or eliminated. Needless to say that the experience of the practicing physician represents the ultimate discriminating factor. OCT are occasionally self-prescribed but are usually prescribed by general practitioners, gynecologists, endocrinologists, and internal medicine experts. In doubtful cases, these physicians should consult with a coagulation expert who has had an interest in the field. One has to remember that a deep venous thrombosis may have several evolutions-complete resolution if promptly treated, a post-phlebitic syndrome or, unfortunately a nonfatal or even fatal pulmonary embolism (35, 36) . One may have a fair knowledge of when a deep venous thrombosis appears, but one has no knowledge of how a deep venous thrombosis may evolve. Over the past 3 years we have been following this approach and so far, after having directly prescribed or controlled along these guidelines the prescriptions made by other physicians, approximately 200 patients of 420 patients/year observation, we have observed no thrombotic complications.
